Skip to main content

CCTG Connection



Published:
Category: News
2023 Practicum Central Office Visit

Congrats to the 2023-2024 Practicum participant who successfully completed their in person visit to CCTG Central Offices in Kingston, Ontario October 5th 6th, 2023. During their visit the group participated in the following sessions:

Read More

Published:
Category: Publications
Publications from CRC6 (NCT01150045) Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
 
Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance).
Read More

Published:
Category: Publications
The results of CCTG BR36 trial, recently published in the journal Nature Medicine, suggest that circulating tumor DNA (ctDNA) analyses could be used as an early marker of immunotherapy response and may help guide therapy. Read More



Published:
Category: Group updates
Oral Agents to Participants in CCTG Clinical Trials

As clinical trial sponsor, the Canadian Cancer Trials Group (CCTG) is responsible for the oversight of the investigational medicinal product(s) (IMPs) used in its clinical trials. CCTG’s policies and requirements are intended to ensure participant safety and adherence with applicable regulations.

Read More

Published:
Category: Group updates
CCTG is seeking a new Senior Investigator

CCTG is seeking an outstanding and visionary cancer trialist for the position of Senior Investigator (SI). Expertise in cancer clinical trial methods and conduct is required. Interest/expertise in investigational new drugs, symptom science/supportive care, patient reported outcomes, application of real world evidence and clinical trials is desirable but not required. As one of our Senior Investigators you will be co-principal investigator of individual trials, and leader within the CCTG program and the CCTG scientific committees.

Read More

Published:
Category: News
Dr. Philippe Bedard presented with the Michaele C. Christian Oncology Drug Development Award

Congratulations to Dr. Philippe Bedard who was recently honoured with the 17th annual Michaele C. Christian Oncology Drug Development Award at the NCI CTEP Early Drug Development Meeting.

Read More

Published:
Category: News

Everyone at CCTG would like to congratulate Dr Frances Shepherd who was recently awarded the Lifetime Contribution Prize from the Canadian Cancer Society. She is an international leader in clinical and translational lung cancer research whose work has transformed the standard of care for patients in Canada and around the world.

Read More

Published:
Category: Publications
LY17: Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell Lymphoma publication
 
Hilton LK, Ngu HS, Collinge B, Dreval K, Ben-Neriah S, Rushton CK, Wong JCH, Cruz M, Roth A, Boyle M, Meissner B, Slack GW, Farinha P, Craig JW, Gerrie AS, Freeman CL, Villa D, Rodrigo JA, Song K, Crump M, Shepherd L, Hay AE, Kuruvilla J, Savage KJ, Kridel R, Karsan A, Marra MA, Sehn LH, Steidl C, Morin RD, Scott DW. Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell Lymphoma.
Read More